Skip to main content
. 2022 Oct 25;2022:4766992. doi: 10.1155/2022/4766992

Figure 5.

Figure 5

Selection and clinical validation of m6A-modified target genes. (a) Peaks of the upregulated m6A-modified target genes. (b) Peaks of the downregulated m6A-modified target genes. (c) Target genes of m6A modification were detected by RT-PCR. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 (n = 40, paired t-test). (d) Protein expression of m6A modification was detected by western blot. ∗∗∗p < 0.001 (n = 6, paired t-test). (e) Macrophage marker expression. ∗∗∗p < 0.001 (n = 20, paired t-test). (f) Correlational analysis of m6A-modified target genes and RF. (g) Correlational analysis of m6A-modified target genes and CCP. (h) ROC curve analysis of m6A-modified target genes in RA.